What the research shows
Researchers studied obese and lean mice. In a separate experiment, they compared mice lacking the beta-3 adrenergic receptor with controls. They measured changes in body weight and fat breakdown to investigate the receptor’s role. The experiment gives evidence about a mechanism in mice. Read the mouse study.
FDA’s review of the clinical program describes a 24-week oral study that failed to establish a significant weight-loss advantage over placebo. The human result addresses a different question from the laboratory measurements. Read FDA’s AOD-9604 review.
Documented formats
The human program included oral preparations. FDA reviewed submitted forms of the bulk substance. Results from an oral study should be attributed to the formulation and route the trial used.
Testing and purity
Look for the exact sequence, salt form and evidence for the intended disulfide bond, which joins two points on the chain. A headline purity percentage cannot establish those details.
How to read a batch reportQuestions about AOD-9604
Is AOD-9604 the same as full-length growth hormone?
It is much shorter. It was designed around one region of the hormone and has its own evidence base.
Does a result for fat breakdown show weight loss in patients?
Fat breakdown in an experimental system and a sustained difference in body weight between trial groups are different outcomes. The human trial measured the latter.